EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur iD, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A Shammas iD, Adam S Sperling iD, Paul G Richardson, Florence Magrangeas iD, Stephane Minvielle iD, Aurore Perrot iD und 7 weitere

Blood · 06.04.2023 · 141 (14) · 1724-1736

DOI: 10.1182/blood.2022017094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 06.04.2023. Verfasst von Mehmet Kemal Samur und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Science, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse in the IFM 2009 study. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD + HDM. Although the number of mutations was similar at diagnosis in both groups (7137 vs 7230; P = .67), the HDM group had significantly more mutations at relapse (9242 vs 13 383, P = .005). No change in the frequency of copy number alterations or structural variants was observed. The newly acquired mutations were typically associated with DNA damage and double-stranded breaks and were predominantly on the transcribed strand. A machine learning model, using this unique pattern, predicted patients who would receive HDM with high sensitivity, specificity, and positive prediction value. Clonal evolution analysis showed that all patients treated with HDM had clonal selection, whereas a static progression was observed with RVD. A significantly higher percentage of mutations were subclonal in the HDM cohort. Intriguingly, patients treated with HDM who achieved complete remission (CR) had significantly more mutations at relapse yet had similar survival rates as those treated with RVD who achieved CR. This similarity could have been due to HDM relapse samples having significantly more neoantigens. Overall, our study identifies increased genomic changes associated with HDM and provides rationale to further understand clonal complexity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansMelphalanNeoplasm Recurrence, LocalBortezomibLenalidomideAntineoplastic Combined Chemotherapy ProtocolsChronic DiseaseTransplantation, AutologousDexamethasone

Substanzen

MelphalanBortezomibLenalidomideDexamethasone

Autor:innen und Institutionen

  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Zurich University Hospital, Zurich, Switzerland.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY.
  • Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA.

ORCID-Profile: Anil Aktas Samur, Masood A Shammas, Adam S Sperling, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Anjan Thakurta, Giovanni Parmigiani, Hervé Avet-Loiseau

Förderung

  • NCI NIH HHS
  • BLRD VA

Zitieren

APA

Samur, M. K., Roncador, M., Aktas Samur, A., Fulciniti, M., Bazarbachi, A. H., Szalat, R., Shammas, M. A., Sperling, A. S., Richardson, P. G., Magrangeas, F., Minvielle, S., Perrot, A., Corre, J., Moreau, P., Thakurta, A., Parmigiani, G., Anderson, K. C., Avet-Loiseau, H., & Munshi, N. C. (2023). High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood, 141(14), 1724-1736. https://doi.org/10.1182/blood.2022017094

Vancouver

Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023;141(14):1724-1736. doi:10.1182/blood.2022017094

BibTeX
@article{Samur2023,
  author = {Samur, Mehmet Kemal and Roncador, Marco and Aktas Samur, Anil and Fulciniti, Mariateresa and Bazarbachi, Abdul Hamid and Szalat, Raphael and Shammas, Masood A and Sperling, Adam S and Richardson, Paul G and Magrangeas, Florence and Minvielle, Stephane and Perrot, Aurore and Corre, Jill and Moreau, Philippe and Thakurta, Anjan and Parmigiani, Giovanni and Anderson, Kenneth C and Avet-Loiseau, Hervé and Munshi, Nikhil C},
  title = {High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {14},
  pages = {1724--1736},
  doi = {10.1182/blood.2022017094}
}
Kostenlos starten →